Aratana Therapeutics, Inc. (NASDAQ:PETX) insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $6.24, for a total transaction of $312,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Aratana Therapeutics, Inc. (NASDAQ PETX) traded down 2.06% during mid-day trading on Wednesday, reaching $6.19. 247,075 shares of the company’s stock were exchanged. The company’s market cap is $266.18 million. Aratana Therapeutics, Inc. has a 52-week low of $4.97 and a 52-week high of $10.50. The stock has a 50-day moving average price of $5.85 and a 200 day moving average price of $6.17.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. The business had revenue of $5.16 million during the quarter, compared to analysts’ expectations of $4.50 million. During the same period in the prior year, the business earned $0.61 EPS. Aratana Therapeutics’s revenue for the quarter was down 86.4% compared to the same quarter last year. Equities analysts predict that Aratana Therapeutics, Inc. will post ($1.09) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Aratana Therapeutics, Inc. (PETX) Insider Peter Steven St Sells 50,000 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/04/aratana-therapeutics-inc-petx-insider-peter-steven-st-sells-50000-shares.html.

PETX has been the topic of a number of research analyst reports. Jefferies Group LLC set a $8.00 price objective on shares of Aratana Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 8th. Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research report on Tuesday, July 4th. BidaskClub downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. ValuEngine raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Finally, Lake Street Capital lowered their price objective on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Aratana Therapeutics has an average rating of “Hold” and an average price target of $8.25.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in shares of Aratana Therapeutics by 281.4% during the 1st quarter. Wells Fargo & Company MN now owns 276,152 shares of the biopharmaceutical company’s stock worth $1,464,000 after acquiring an additional 203,738 shares in the last quarter. Baird Financial Group Inc. grew its stake in shares of Aratana Therapeutics by 32.0% during the 1st quarter. Baird Financial Group Inc. now owns 40,758 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 9,880 shares in the last quarter. American International Group Inc. grew its stake in shares of Aratana Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,354 shares in the last quarter. Financial Counselors Inc. bought a new position in shares of Aratana Therapeutics during the 1st quarter worth approximately $101,000. Finally, Vanguard Group Inc. grew its stake in shares of Aratana Therapeutics by 13.9% during the 1st quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock worth $10,211,000 after acquiring an additional 235,208 shares in the last quarter. 73.04% of the stock is owned by institutional investors and hedge funds.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.